Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.
Gongyan Chen(Harbin Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Cheng(Jilin Province Tumor Hospital), Jian Feng(Okayama University), Xiaodong Zhang(Shanghai Jiao Tong University), Lejie Cao(Anhui Provincial Hospital), Aimin Zang, Lin Wu(Materials Systems (United States)), Yuping Li(Binzhou Medical University), Xiang Wang, Chunling Liu(Xinjiang Medical University), Shucai Zhang(Northeastern University), Hui Zhao(Dalian Medical University), Chuan Gu, Jiwei Liu(Mongolian University of Science and Technology), Shuyang Zhu(Xuzhou Medical College), Yunpeng Liu(Shenyang Institute of Automation), Yanrong Hao(The People's Hospital of Guangxi Zhuang Autonomous Region), Fei Liu(Cangzhou Central Hospital), Jiuwei Cui(Jilin University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k